Erythropoietin is special type of protein biomarker, also known as a growth factor. It acts by the stimulating the bone marrow to manufacture red blood cells. There are five different types of erythropoietin biomarkers such as epoetin alfa, epoetin beta, epoetin zeta, epoetin theta and darbepoetin alfa. Erythropoietin is mostly administered subcutaneously as an alternative to iron supplements. Erythropoietin used in human beings is also known as recombinant human erythropoietin (rHuEPO). Commercially available rHuEPO has the same 165 amino acid sequence as available in naturally occurring hormone but the level of glycosylation in rHuEPO depends on the testing method used. Growing global incidence of renal diseases and cancers is expected to create a marked increase in use of EPO biomarkers.
EPO Biomarkers Market: Drivers & Restraints
The prime drivers for the market include growing incidence of cancers and renal diseases. Changes in lifestyle and improper eating habits contribute to pancreatic and endocrine cancers, which often lead to severe anaemia, where external erythropoietin infusion is required. Other drivers for the EPO biomarker market is technological advancement in devising proprietary testing methods apart from tried and tested ones.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1382
Restraints for the market include lack of availability of skilled labour and sufficient quality controlled testing laboratories in most countries in less developed regions. Insufficient R&D in identification of biomarkers due to adoption of cost cutting measures in European regions is expected to restrain proper quantitative assessment of drugs and their therapeutic efficacy in blood. This could also hamper progress of ongoing clinical trials and proper stratification of patients.
EPO Biomarkers Market: Segmentation
EPO Biomarkers is classified on the basis of biomarker, indication, testing method and end user type:
Based on biomarker type, the global EPO Biomarkers is segmented into the following:
- Recombinant human erythropoietin
- Erythropoietin alfa
- Erythropoietin beta
- Erythropoietin zeta
- Erythropoietin theta
- Darbepoietin alfa
Based on indication, the global EPO Biomarkers is segmented into following:
- End stage renal disorder
- Rheumatoid arthritis
Based on end users, the global EPO Biomarkers is segmented into the following:
- Diagnostic centers
- Ambulatory care and surgical centers
EPO Biomarkers Market: Overview
EPO biomarker market is account to rise in value during the forecast period. Due to expansion in the product segment of EPO biomarkers the market share will be rising with a promising rate, also with the increase in demand for diagnosis and treatment of widely spread chronic disease the EPO market is expected to grow with a promising CAGR during the forecast period. Biologic drug industry is investing on R&D and the key players are focusing on increasing their production capacity for EPO biomarkers.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1382
EPO Biomarkers Market: Region-wise Outlook
Considering all potential geographic regions, EPO biomarkers market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Japan, Asia Pacific and Middle East & Africa. North America is been dominating in the EPO biomarkers due to rise in acceptance for bio-similar weakly followed by Western and Eastern Europe, Asia Pacific has a dominating presence in EPO biomarker market and most of the key players are locally producing the EPO biomarkers, that is enhancing their market share and product reach. There is a good opportunity for Japan in EPO biomarker market. The emerging regions in Asia Pacific, Middle East and Africa holds promising future for rise in EPO biomarker market, due to increase in awareness towards the chronic disease and increase in population simultaneously.
EPO Biomarkers Market: Key Players
Shandong Kexing Bioproducts Co., Ltd., Amgen Inc., Ranbaxy Laboratories Ltd, Johnson & Johnson, Roche Holding AG, Sigma-Aldrich, Thermo Fisher Scientific, Hospira Inc., Biocon, Teva Pharmaceutical Industries Ltd.,